Echelard Yann 4

What Happened
Yann Echelard, a director of TG Therapeutics (TGTX), received a grant of 8,325 stock tracking units (STUs) on 2026-06-11. The award was granted at $0.00 (no cash paid) and is reported as a derivative award. The STUs are contingent rights that could convert to common shares or a cash payment equal to the fair market value of one share at the committee’s discretion once vested.

Key Details

• Transaction date: 2026-06-11; Filing date: 2026-06-15 (filed within the SEC two-business-day rule).
• Grant: 8,325 STUs; reported acquisition price $0.00.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Footnote summary: F1 — each STU may convert to one share or a cash payment equal to one share’s fair market value, as determined by the board committee, payable no later than 30 days after the first anniversary of the grant. F2 — STUs vest on the first anniversary of the grant provided continuous service through that date.

Context
This was an award grant (not an open-market purchase or sale). Because conversion and payout are contingent on vesting and the committee’s choice of stock vs. cash, the grant does not immediately change outstanding common shares and should be viewed as compensation rather than a straightforward insider buy or sell.